Journey Medical 3Q 2026: Revenue $18.97M, EPS ($0.05) — 10-Q Summary
Journey Medical reported 3Q 2026 revenue of $18.97M, up 8% YoY, with net loss narrowing 43% to $1.32M. Emrosi sales grew 84% YoY to $9.0M, while Qbrexza and legacy products saw declines. The company paid $4.1M in vendor settlements.
How this was made

The 30-second read
Why it matters
The earnings release adds a fresh data point for the company but lacks a transformative catalyst; market reaction is expected to be muted.
Market read
Micro‑cap earnings release with modest financial improvement; limited immediate trading impact.
What to watch
Potential impact of the vendor settlement expense on cash flow and future profitability.
Background
Journey Medical Corp (NASDAQ: DERM) filed its Form 10‑Q for Q3 2026, showing incremental revenue growth and a significant reduction in net loss.
Ticker impact
Journey Medical reported Q3 2026 revenue of $18.97M and a narrowed net loss, marking its first public disclosure of these quarterly results.
limited upside as investors digest modest improvement; likely modest price stability.
The numbers are new but small in absolute terms; no major guidance change or catalyst to drive a strong move.
Market effects
Provides a modest data point for the dermatology device sector but unlikely to shift sector sentiment.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global relevance given the company's size and niche market.
Counterpoint
If the loss narrowing continues, the stock could be undervalued relative to peers.
Key entities
- companyJourney Medical Corp
Dermatology device manufacturer reporting Q3 2026 results.

